Researchers from Bochum and Osnabrück have gained new insights into the structure of the Ras protein, which acts as a molecular switch for cell growth and is involved in the development of cancer.

Researchers from Regor Therapeutics Inc. presented data from the company’s discovery campaign of Son of sevenless homolog 1 (SOS1) inhibitors, which show potential for the treatment of mutated ...

BAY3498264 is an investigational oral selective SOS1 inhibitor with potential to treat a variety ... found in up to 85% of cancers driven by RAS alterations 1 In-house developed compound is being ...

17, 2020 /PRNewswire/ -- Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a SOS1::pan-KRAS ...

Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264, an investigational oral selective SOS1 inhibitor, to assess its safety ...